本帖最后由 老马 于 2012-1-13 21:20 编辑
# y9 e1 |: U! E6 C4 _4 L9 \3 y+ p% ~! Z# `) o3 {- o, j; G- {0 Z
爱必妥和阿瓦斯丁的比较
+ J, c3 [* _1 h
: [) N! l) \+ Fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/+ o7 }. G" y" K1 A
, d6 m2 I2 {8 ^; m8 U
0 l( N+ ~( R( j/ Whttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
8 Q# Y3 f0 r& v==================================================" B9 ]' |: }5 P4 v( o- n1 T, ?
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
K T5 Q- g1 DPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.7 i3 }0 c, [8 N& S+ x r
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 \& I3 y& m5 S. H3 \% l0 `7 g9 o
|